• AC Immune reported positive preliminary Phase 1 results for ACI-19764, an oral NLRP3 inhibitor, with results already presented as interim data.
• Early readout showed the drug was safe and well tolerated, with evidence it reached the central nervous system.
• Development focus now shifts to a Phase 1b cohort in cardiovascular-risk patients to gauge anti-inflammatory activity; initial results are expected by year end.
• Full Phase 1/1b results are slated for H1 2027, setting the timeline for next-stage clinical and partnering decisions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608200700OMX_____CNEWS_EN_GNW1001258384_en) on August 20, 2026, and is solely responsible for the information contained therein.